189 filings
Page 8 of 10
6-K
2feys5ctnsek33vb1p
7 Mar 19
Current report (foreign)
11:00am
6-K
ikdln881k1
28 Feb 19
Current report (foreign)
10:31am
6-K
2sjaf6576s5bf
23 Jan 19
Company announcement — No. 1/2019
3:09pm
6-K
ufll14r30w71yl1k
4 Jan 19
Zealand Pharma completes equity investment in strategic partner Beta Bionics
4:47pm
6-K
zn3pekk
14 Dec 18
Current report (foreign)
7:55am
6-K
s0vi86 61zyk9yjedj
26 Nov 18
Zealand Pharma announces change in Executive Management
1:12pm
6-K
wpo62
16 Nov 18
Zealand Pharma — Interim report for the first nine months of 2018
11:03am
6-K
4v6r7o27vf539nbeh4j6
26 Oct 18
Current report (foreign)
9:22am
6-K
r83s5n dca
15 Oct 18
Current report (foreign)
7:27am
6-K
kb0ovtzop o33uku
1 Oct 18
Zealand Pharma expands leadership team and appoints Marino Garcia as Senior Vice President of Corporate & Business Development
12:00am
6-K
wf8a q1y57wr6kurdk
19 Sep 18
Zealand Pharma achieves primary and key secondary endpoints in pivotal Phase 3 trial with dasiglucagon for severe hypoglycemia
6:05am
6-K
8h63 m0gr3
17 Sep 18
Current report (foreign)
12:00am
6-K
1ewejtdnh8
14 Sep 18
Current report (foreign)
12:00am
6-K
vmi9om6ql w2s
7 Sep 18
Current report (foreign)
12:00am
6-K
7ys25w0fclf6gb
17 Aug 18
Zealand Pharma — Interim report for the first half of 2018
6:06am
6-K
w4jie3tk8w
31 Jul 18
Zealand announces an 85% increase in Soliqua® 100/33/ Suliqua® royalty revenue from first to second quarter of 2018
8:37am
6-K
fs4n7a3s26qsq75
11 Jul 18
Current report (foreign)
2:12pm
6-K
10lqqcb
31 May 18
Current report (foreign)
11:34am
6-K
6d3p804j
29 May 18
Zealand Pharma reports completion of the second and pivotal Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia
7:04am
6-K
cvqlbbygp9
22 May 18
Current report (foreign)
8:09am